Literature DB >> 26337932

Prospective study of plasma D-dimer and incident venous thromboembolism: The Atherosclerosis Risk in Communities (ARIC) Study.

Aaron R Folsom1, Alvaro Alonso2, Kristen M George2, Nicholas S Roetker2, Weihong Tang2, Mary Cushman3.   

Abstract

INTRODUCTION: Plasma D-dimer is a useful clinical test for acute venous thromboembolism (VTE), and concentrations remain higher in VTE patients after treatment than in controls. Yet, evidence is limited on whether higher basal D-dimer concentrations in the general population are associated with greater risk of first VTE.
OBJECTIVE: To assess the prospective association between D-dimer and incident VTE over a long follow-up.
METHODS: We measured plasma D-dimer in 12,097 participants, initially free of VTE, in the Atherosclerosis Risk in Communities Study. Over a median follow-up of 17years, we identified 521 VTEs. We calculated hazard ratios of VTE using proportional hazards regression.
RESULTS: The age, race, and sex adjusted hazard ratios of VTE across quintiles of D-dimer were 1, 1.5, 1.8, 2.1, and 3.2 (p for trend <0.0001). For the first 10years of follow-up, the hazard ratio for the highest versus lowest quintile was 3.5, and was 2.9 after 10years. In both whites and African Americans, VTE risk remained strongly associated with D-dimer after further adjustment for diabetes, body mass index, kidney function, and several thrombophilia genetic markers. D-dimer was associated with both unprovoked and provoked VTE, but more strongly with unprovoked.
CONCLUSIONS: A higher basal level of plasma D-dimer in the general population, presumably reflecting a predisposition to thrombosis, is a strong, long-term risk factor for a first VTE.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  D-dimer; Deep vein thrombosis; Prospective studies; Pulmonary embolism; Risk factors

Mesh:

Substances:

Year:  2015        PMID: 26337932      PMCID: PMC4577468          DOI: 10.1016/j.thromres.2015.08.013

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  24 in total

1.  Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples.

Authors:  M R Lewis; P W Callas; N S Jenny; R P Tracy
Journal:  Thromb Haemost       Date:  2001-12       Impact factor: 5.249

2.  Ideal cardiovascular health: associations with biomarkers and subclinical disease and impact on incidence of cardiovascular disease in the Framingham Offspring Study.

Authors:  Vanessa Xanthakis; Danielle M Enserro; Joanne M Murabito; Joseph F Polak; Kai C Wollert; James L Januzzi; Thomas J Wang; Geoffrey Tofler; Ramachandran S Vasan
Journal:  Circulation       Date:  2014-10-01       Impact factor: 29.690

3.  Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy.

Authors:  G Lowe; M Woodward; M Vessey; A Rumley; P Gough; E Daly
Journal:  Thromb Haemost       Date:  2000-04       Impact factor: 5.249

4.  D-dimer as a risk factor for deep vein thrombosis: the Leiden Thrombophilia Study.

Authors:  Astrid C M Andreescu; Mary Cushman; Frits R Rosendaal
Journal:  Thromb Haemost       Date:  2002-01       Impact factor: 5.249

Review 5.  Statins for primary prevention of venous thromboembolism.

Authors:  Lun Li; Peizhen Zhang; Jin Hui Tian; KeHu Yang
Journal:  Cochrane Database Syst Rev       Date:  2014-12-18

6.  American Heart Association's Life's Simple 7 and incidence of venous thromboembolism.

Authors:  Aaron R Folsom; Nels C Olson; Pamela L Lutsey; Nicholas S Roetker; Mary Cushman
Journal:  Am J Hematol       Date:  2015-02-05       Impact factor: 10.047

7.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.

Authors: 
Journal:  Am J Epidemiol       Date:  1989-04       Impact factor: 4.897

8.  Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology.

Authors:  Mary Cushman; Albert W Tsai; Richard H White; Susan R Heckbert; Wayne D Rosamond; Paul Enright; Aaron R Folsom
Journal:  Am J Med       Date:  2004-07-01       Impact factor: 4.965

9.  American Heart Association's Life's Simple 7 and risk of venous thromboembolism: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study.

Authors:  Nels C Olson; Mary Cushman; Suzanne E Judd; Leslie A McClure; Susan G Lakoski; Aaron R Folsom; Monika M Safford; Neil A Zakai
Journal:  J Am Heart Assoc       Date:  2015-02-27       Impact factor: 5.501

Review 10.  Hemostatic factors and risk of coronary heart disease in general populations: new prospective study and updated meta-analyses.

Authors:  Peter Willeit; Alexander Thompson; Thor Aspelund; Ann Rumley; Gudny Eiriksdottir; Gordon Lowe; Vilmundur Gudnason; Emanuele Di Angelantonio
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

View more
  22 in total

1.  Circulating ceruloplasmin, ceruloplasmin-associated genes and the incidence of venous thromboembolism in the Atherosclerosis Risk in Communities study.

Authors:  Antonio P Arenas de Larriva; Alvaro Alonso; Faye L Norby; Nicholas S Roetker; Aaron R Folsom
Journal:  J Thromb Haemost       Date:  2019-03-18       Impact factor: 5.824

2.  Sex-Based Differences in Cardiometabolic Biomarkers.

Authors:  Jeanney Lew; Monika Sanghavi; Colby R Ayers; Darren K McGuire; Torbjørn Omland; Dorothee Atzler; Maria O Gore; Ian Neeland; Jarett D Berry; Amit Khera; Anand Rohatgi; James A de Lemos
Journal:  Circulation       Date:  2017-02-07       Impact factor: 29.690

Review 3.  Importance of Genetic Studies of Cardiometabolic Disease in Diverse Populations.

Authors:  Lindsay Fernández-Rhodes; Kristin L Young; Adam G Lilly; Laura M Raffield; Heather M Highland; Genevieve L Wojcik; Cary Agler; Shelly-Ann M Love; Samson Okello; Lauren E Petty; Mariaelisa Graff; Jennifer E Below; Kimon Divaris; Kari E North
Journal:  Circ Res       Date:  2020-06-04       Impact factor: 17.367

4.  Elevated D-dimer levels in African Americans with sickle cell trait.

Authors:  Rakhi P Naik; James G Wilson; Lynette Ekunwe; Stanford Mwasongwe; Qing Duan; Yun Li; Adolfo Correa; Alexander P Reiner
Journal:  Blood       Date:  2016-03-11       Impact factor: 22.113

5.  Plasma Concentrations of High Molecular Weight Kininogen and Prekallikrein and Venous Thromboembolism Incidence in the General Population.

Authors:  Aaron R Folsom; Weihong Tang; Saonli Basu; Jeffrey R Misialek; David Couper; Susan R Heckbert; Mary Cushman
Journal:  Thromb Haemost       Date:  2019-02-19       Impact factor: 5.249

6.  Reasons for Differences in the Incidence of Venous Thromboembolism in Black Versus White Americans.

Authors:  Aaron R Folsom; Saonli Basu; Ching-Ping Hong; Susan R Heckbert; Pamela L Lutsey; Wayne D Rosamond; Mary Cushman
Journal:  Am J Med       Date:  2019-04-04       Impact factor: 4.965

Review 7.  Pulmonary Embolism for the Cardiologist: Emphasis on Diagnosis.

Authors:  Jonathan Halevy; Mary Cushman
Journal:  Curr Cardiol Rep       Date:  2018-09-26       Impact factor: 2.931

8.  Prospective Study of Endogenous Hormones and Incidence of Venous Thromboembolism: The Atherosclerosis Risk in Communities Study.

Authors:  Nicholas S Roetker; Richard F MacLehose; Ron C Hoogeveen; Christie M Ballantyne; Saonli Basu; Mary Cushman; Aaron R Folsom
Journal:  Thromb Haemost       Date:  2018-10-08       Impact factor: 5.249

9.  Clinical Outcomes Associated With Sickle Cell Trait: A Systematic Review.

Authors:  Rakhi P Naik; Kim Smith-Whitley; Kathryn L Hassell; Nkeiruka I Umeh; Mariane de Montalembert; Puneet Sahota; Carlton Haywood; Jean Jenkins; Michele A Lloyd-Puryear; Clinton H Joiner; Vence L Bonham; Gregory J Kato
Journal:  Ann Intern Med       Date:  2018-10-30       Impact factor: 25.391

10.  Burden of rare exome sequence variants in PROC gene is associated with venous thromboembolism: a population-based study.

Authors:  Weihong Tang; Mary Rachel Stimson; Saonli Basu; Susan R Heckbert; Mary Cushman; James S Pankow; Aaron R Folsom; Nathan Pankratz
Journal:  J Thromb Haemost       Date:  2019-12-06       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.